Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer

Condition(s) studied

Investigational drug(s) / intervention(s)

Brigatinib: Brigatinib Tablets

Study summary

This study is a survey in Japan of Brigatinib tablets used to treat Japanese people with non-small cell lung cancer. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.

The main aim of the study is to check for side effects related to lung disease from Brigatinib. During the study, participants with non-small cell lung cancer will take Brigatinib tablets according to their clinic's standard practice. The study doctors will check for side effects from Brigatinib for 1 year.

Eligibility

Primary outcome measure(s)

• Number of Participants with Adverse Events Related to Interstitial Lung Disease — Up to 1 year
  An adverse event (AE) is any untoward or undesirable medical occurrence in a participant linked in time with the use of a pharmaceutical/ medicinal product. They are not limited to the events with clear causal relationship with treatment with concerned drug. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.

Trial sites (1)

More Takeda trials in Japan

Other trials for the same condition